
Stereotaxis Inc (STXS) Stock Forecast & Price Target
Stereotaxis Inc (STXS) Analyst Ratings
Bulls say
Stereotaxis is poised for a strong second half of 2026 and fiscal year 2027, with "green shoots" already emerging for its MAGiC catheter and a growing demand for its robotic systems. Despite missing Q1 revenue estimates and facing headwinds in its disposable business, the company's efforts to ramp production of the catheter and expand its installed base bode well for future growth. As a result, the optimistic outlook for Stereotaxis's recurring revenues and growing pipeline of system sales make it a bullish investment opportunity.
Bears say
Stereotaxis is facing challenges in meeting its revenue projections due to delays in system sales and the slow adoption of new technologies by healthcare providers. There are also potential risks related to collaboration with other manufacturers and suppliers, installation and regulatory issues, and competition in the market. Despite its promising technology, the company's financial performance may be negatively impacted by these factors.
This aggregate rating is based on analysts' research of Stereotaxis Inc and is not a guaranteed prediction by Public.com or investment advice.
Stereotaxis Inc (STXS) Analyst Forecast & Price Prediction
Start investing in Stereotaxis Inc (STXS)
Order type
Buy in
Order amount
Est. shares
0 shares